Vaxil Bio Ltd.
VXL.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 74.10K | 58.40K | 84.60K | 104.50K | 205.40K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 97.80K | 80.60K | 139.30K | 188.70K | 339.00K |
| Operating Income | -97.80K | -80.60K | -139.30K | -188.70K | -339.00K |
| Income Before Tax | -95.60K | -80.60K | -139.30K | -188.70K | -335.30K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.10 | -0.08 | -0.14 | -0.19 | -0.34 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -95.60K | -80.60K | -139.30K | -188.70K | -335.30K |
| EBIT | -97.80K | -80.60K | -139.30K | -188.70K | -339.00K |
| EBITDA | 23.20K | -1.00K | -95.20K | -187.20K | -337.90K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 547.92M | 547.92M | 547.92M | 547.92M | 547.92M |
| Average Diluted Shares Outstanding | 547.92M | 547.92M | 547.92M | 547.92M | 547.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
